Maricar Malinis

I joined the faculty of the Section of Infectious Diseases in 2013. I am an Associate Professor of Medicine with secondary appointment in the Department of Surgery (Transplant). I am the Medical Director of Transplant and Oncology Infectious Diseases Program.

I obtained my bachelor of science in Chemistry at the University of Philippines Diliman and my medical degree at the University of Philippines College of Medicine. I completed internal medicine residency at Seton Hall Graduate Medical Education. Afterwards, I did fellowships in Geriatric Medicine at University of Michigan, Infectious Diseases at University of Louisville, and Transplant Infectious Diseases at Cleveland Clinic Foundation.

I am an active member of the American Society of Transplantation (AST) and the AST Infectious Diseases Community of Practice (IDCOP). I am currently the Chair of the AST IDCOP Older Adult Working Group which is focused on clinical outcomes of transplant-related infections in older adults. In addition, I am currently the Member-at-large of the AST ID COP and Councilor of the Transplant Infectious Diseases Section of the Transplantation Society. I am also an active member of the Infectious Diseases Society of America and currently a Committee Member of the Clinical Affairs Committee and Digital Advisory Group. In 2020, I completed my 3-year term as a Member-at-large of Organ Procurement Transplant Network Ad hoc Disease Transmission Advisory Committee .

I am involved in clinical teaching of medical students, residents and fellows. Due to growing interest in Transplant Infectious Diseases, we created a curriculum specific for 2nd year ID fellows who want pursue a career in this field. Since 2015, we had 6 fellows who completed a 2nd year Clinical Track focused on Transplant Infectious diseases.

My research is focused on clinical outcomes of transplantation in people living with HIV and older adults. I have participated in several multi-center studies, including clinical trials. I am the primary investigator of the HOPE Act study at Yale and several multi-center clinical trials of novel anti-viral agents for immunocompromised hosts.